ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 02/13/24

NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today ann...

2024-02-07 02:32:48 ET Summary Zentalis Pharmaceuticals is positioned to become an oncology leader with its lead drug candidate, azenosertib, showing promising results in difficult-to-treat cancers. The company's financial health is strong, with a healthy cash reserve that will su...

2024-02-05 09:00:14 ET Summary Zentalis Pharma has shelved its oral SERD and EGFR inhibitors due to competition and focused on ZN-c3, an inhibitor of WEE1. AZN left the WEE1 space last year, which is a cause for both worry and elation at ZNTL. ZNTL's pivotal data will only rea...

Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager, Appointed Chief Business Officer NEW YORK and SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Zentalis ®...

- Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - - Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs - - Zentalis to receive up-front payment of $35 million in cash and Immunome comm...

2023-12-30 05:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-22 17:56:28 ET Summary The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success usi...

2023-12-14 17:14:15 ET Gainers: PLAYSTUDIOS ( MYPS ) +4% . Zentalis Pharmaceuticals ( ZNTL ) +4% . ContextLogic  ( WISH ) +3% . eXp World Holdings ( EXPI ) +3% . Losers: IN8bio ( INAB ) -12% . Scholastic Corporation ...

2023-11-14 13:22:34 ET More on Zentalis Pharmaceuticals Zentalis: Latest Market Sell-Off Looks Justified With Data Catalysts Long Way Off Zentalis: A Buy As Small Molecule Trials Continue To Advance Wedbush cuts Zentalis to neutral, cites strategy shift for ovarian c...

2023-11-14 10:35:54 ET Summary Zentalis is a biotech company focused on developing Azenosertib, a Wee1 inhibitor, for ovarian cancer. The company has faced stock sell-offs due to mixed data from clinical trials of Azenosertib in combination with chemotherapy, and as a monotherapy....